Fiche publication


Date publication

avril 2025

Journal

Biosensors

Auteurs

Membres identifiés du Cancéropôle Est :
Dr WACOGNE Bruno


Tous les auteurs :
Wacogne B, Brito M, Gamonet C, Rouleau A, Frelet-Barrand A

Résumé

The production of advanced therapy medicinal products (ATMP) is a long and highly technical process, resulting in a high cost per dose, which reduces the number of eligible patients. There is a critical need for a closed and sample-free monitoring system to perform the numerous quality controls required. Current monitoring methods are not optimal, mainly because they require the system to be opened up for sampling and result in material losses. White light spectroscopy has emerged as a technique for sample-free control compatible with closed systems. We have recently proposed its use to monitor cultures of CEM-C1 cell lines. In this paper, we apply this method to T-cells isolated from healthy donor blood samples. The main differences between cell lines and human primary T-cells lie in the slightly different shape of their absorption spectra and in the dynamics of cell expansion. T-cells do not multiply exponentially, resulting in a non-constant generation time. Cell expansion is described by a power-law model, which allows for the definition of instantaneous generation times. A correlation between the linear asymptotic behavior of these generation times and the initial cell concentration leads to the hypothesis that this could be an early predictive marker of the final culture concentration. To the best of our knowledge, this is the first time that such concepts have been proposed.

Mots clés

CAR T-cell, advanced therapy medicinal product, cell concentration monitoring, quality control, white light spectroscopy

Référence

Biosensors (Basel). 2025 04 15;15(4):